Presented at ESMO Congress 2024, results from the phase 1b CodeBreaK study in patients with KRAS G12C-mutated metastatic colorectal cancer…
Elena Élez
Announced by the European Medicines Agency (EMA) last month, June 21, the highly selective and potent VEGFR inhibitor fruquintinib has…
Reported today during a Proffered Paper session at the ESMO Gastrointestinal Cancers Annual Congress (ESMO GI) 2024*, first health-related quality…
Checkmate 8HW is the first phase III study to assess first-line nivolumab plus ipilimumab in patients with unresectable microsatellite instability-high/mismatch…
Results of the study FRESCO-2 show a statistically and clinically meaningful benefit with a favorable safety profile in patients with…
Published in The Lancet Oncology results of the multicenter phase II MOUNTAINEER study (1) show that tucatinib plus trastuzumab had…
The New England Journal of Medicine publishes today the results of the SUNLIGHT study, a Phase III clinical trial comparing…
Published ahead of print in Nature Medicine*, the final efficacy and safety results of the ROAR basket study led by…
A study led by researchers at the Hospital del Mar Medical Research Institute shows that the oxaliplatin administered in some…
Published in Nature Medicine, a VHIO-led study has unveiled a new predictive biomarker of response to anti-BRAF/EGFR combinatory therapy in…
